Virtus Investment Advisers Inc. Takes $335,000 Position in MiMedx Group, Inc. (NASDAQ:MDXG)

Virtus Investment Advisers Inc. bought a new position in shares of MiMedx Group, Inc. (NASDAQ:MDXG) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 34,846 shares of the company’s stock, valued at approximately $335,000.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. JPMorgan Chase & Co. raised its position in shares of MiMedx Group by 265.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 297,367 shares of the company’s stock worth $1,757,000 after acquiring an additional 215,995 shares in the last quarter. SG Americas Securities LLC increased its holdings in MiMedx Group by 79.9% in the fourth quarter. SG Americas Securities LLC now owns 83,385 shares of the company’s stock worth $802,000 after purchasing an additional 37,031 shares in the last quarter. Savant Capital LLC acquired a new position in MiMedx Group in the fourth quarter valued at approximately $100,000. Van ECK Associates Corp acquired a new position in MiMedx Group in the fourth quarter valued at approximately $40,000. Finally, Palumbo Wealth Management LLC bought a new position in shares of MiMedx Group during the 4th quarter worth approximately $171,000. Institutional investors and hedge funds own 79.15% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently issued reports on the stock. Cantor Fitzgerald reiterated an “overweight” rating and set a $13.00 target price on shares of MiMedx Group in a research report on Thursday, February 27th. StockNews.com lowered shares of MiMedx Group from a “strong-buy” rating to a “buy” rating in a report on Friday, May 9th.

Insider Transactions at MiMedx Group

In related news, CAO William Frank Iv Hulse sold 81,446 shares of the stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $7.80, for a total transaction of $635,278.80. Following the completion of the sale, the chief accounting officer now directly owns 494,774 shares of the company’s stock, valued at approximately $3,859,237.20. This trade represents a 14.13% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Kimberly Maersk-Moller sold 4,106 shares of the business’s stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $7.89, for a total value of $32,396.34. Following the completion of the transaction, the insider now directly owns 310,836 shares in the company, valued at approximately $2,452,496.04. This represents a 1.30% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 144,018 shares of company stock valued at $1,130,312 over the last ninety days. 1.70% of the stock is currently owned by insiders.

MiMedx Group Trading Down 0.6%

NASDAQ MDXG opened at $7.05 on Monday. MiMedx Group, Inc. has a 52 week low of $5.47 and a 52 week high of $10.14. The business has a 50 day moving average price of $7.19 and a 200-day moving average price of $8.19. The company has a quick ratio of 3.53, a current ratio of 4.10 and a debt-to-equity ratio of 0.10. The company has a market cap of $1.04 billion, a price-to-earnings ratio of 12.82 and a beta of 1.85.

MiMedx Group (NASDAQ:MDXG) last released its quarterly earnings data on Wednesday, April 30th. The company reported $0.06 earnings per share for the quarter, hitting the consensus estimate of $0.06. The firm had revenue of $88.21 million for the quarter, compared to the consensus estimate of $86.32 million. MiMedx Group had a net margin of 23.86% and a return on equity of 26.21%. As a group, equities analysts expect that MiMedx Group, Inc. will post 0.3 earnings per share for the current fiscal year.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.